💊FDA PHARMA today
FDA Approves New Pfizer Biosimilar
Pfizer-developed biosimilar medicine IXIFI™ (infliximab-qbtx) receives FDA approval for all eligible indications
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade®(infliximab)* for all eligible indications of the reference product.1
http://press.pfizer.com/press-release/fda-approves-new-pfizer-biosimilar